# EDGAR Filing Document

**Accession Number:** 0001400118
**File Stem:** 0002069316-25-000001
**Filing Date:** 2025-6
**Character Count:** 9901
**Document Hash:** 878f1048487cef5ea54508b98915c42a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002069316-25-000001.hdr.sgml**: 20250624

**ACCESSION NUMBER**: 0002069316-25-000001

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250624

**DATE AS OF CHANGE**: 20250624

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sagimet Biosciences Inc.
- **CENTRAL INDEX KEY:** 0001400118
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 205991472
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94156
- **FILM NUMBER:** 251067224

**BUSINESS ADDRESS:**
- **STREET 1:** 155 BOVET RD., SUITE 303
- **CITY:** SAN MATEO
- **STATE:** CA
- **ZIP:** 94402
- **BUSINESS PHONE:** (650) 561-8600

**MAIL ADDRESS:**
- **STREET 1:** 155 BOVET RD., SUITE 303
- **CITY:** SAN MATEO
- **STATE:** CA
- **ZIP:** 94402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 3-V Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20070521
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AP11 Ltd
- **CENTRAL INDEX KEY:** 0002069316

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12/F, BUILDING D, NO. 198 QIDI ROAD,
- **STREET 2:** HIPARK, XIAOSHAN DISTRICT
- **CITY:** HANGZHOU
- **NON US STATE TERRITORY:** ZHEJIANG
- **PROVINCE COUNTRY:** F4
- **ZIP:** 311200
- **BUSINESS PHONE:** (86)57185389730

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12/F, BUILDING D, NO. 198 QIDI ROAD,
- **STREET 2:** HIPARK, XIAOSHAN DISTRICT
- **CITY:** HANGZHOU
- **NON US STATE TERRITORY:** ZHEJIANG
- **PROVINCE COUNTRY:** F4
- **ZIP:** 311200

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** Sagimet Biosciences Inc.

**Title of Class of Securities:** Series A common stock

**CUSIP Number:** 786700104

**Date of Event Which Requires Filing of this Statement:** 06/24/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>AP11 Limited | Names of Reporting Persons<br>AP11 Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>D8 | Citizenship or Place of Organization<br>D8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>1504642.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>1504642.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1504642.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1504642.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.9% | Percent of Class Represented by Amount in Row (9)<br>4.9% |
| 12. | Type of Reporting Person (See Instructions)<br>CO, FI | Type of Reporting Person (See Instructions)<br>CO, FI |

**Comment for Type of Reporting Person:** The reported percentage is calculated based on 30,674,855 shares of Series A common stock outstanding as of June 10, 2025, as reported in the Issuer's Form 8-K filed with the Securities and Exchange Commission on June 10, 2025.

---

| 1. | Names of Reporting Persons<br>Ascletis Pharma Inc. | Names of Reporting Persons<br>Ascletis Pharma Inc. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>1504642.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>1504642.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1504642.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1504642.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.9% | Percent of Class Represented by Amount in Row (9)<br>4.9% |
| 12. | Type of Reporting Person (See Instructions)<br>CO, FI | Type of Reporting Person (See Instructions)<br>CO, FI |

**Comment for Type of Reporting Person:** The reported percentage is calculated based on 30,674,855 shares of Series A common stock outstanding as of June 10, 2025, as reported in the Issuer's Form 8-K filed with the Securities and Exchange Commission on June 10, 2025.

---

**Item 1(a). Name of Issuer:**
Sagimet Biosciences Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
155 BOVET RD., SUITE 303, SAN MATEO, CALIFORNIA, 94402

**Item 2(a). Name of Person Filing:**
AP11 Limited
Ascletis Pharma Inc.

**Item 2(b). Address of Principal Business Office:**
AP11 Limited - 12/F, Building D, No. 198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou China, 311200
Ascletis Pharma Inc. - 12/F, Building D, No. 198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou China, 311200

**Item 2(c). Citizenship:**
AP11 Limited - British Virgin Islands
Ascletis Pharma Inc. - Cayman Islands

**Item 2(d). Title of Class of Securities:**
Series A common stock

**Item 2(e). CUSIP Number:**
786700104

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

AP11 Limited - 1,504,642
Ascletis Pharma Inc. - 1,504,642

**(b) Percent of class:**

AP11 Limited - 4.9%
Ascletis Pharma Inc. - 4.9%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

AP11 Limited - 1,504,642
Ascletis Pharma Inc. - 1,504,642

**(ii) Shared power to vote or to direct the vote:**

AP11 Limited - 0
Ascletis Pharma Inc. - 0

**(iii) Sole power to dispose or to direct the disposition of:**

AP11 Limited - 1,504,642
Ascletis Pharma Inc. - 1,504,642

**(iv) Shared power to dispose or to direct the disposition of:**

AP11 Limited - 0
Ascletis Pharma Inc. - 0

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**AP11 Limited**

**Date:** 06/24/2025

**By:** /s/ Huqin Yang

**Name & Title:** Treasurer

**Ascletis Pharma Inc.**

**Date:** 06/24/2025

**By:** /s/ Huqin Yang

**Name & Title:** Treasurer